Presentations to Highlight BioLight's IOPtiMate System at Upcoming European Ophthalmology Conferences
TEL-AVIV, Israel, September 2, 2015 /PRNewswire/ --
BioLight Life Sciences Investments (OTCQX: BLGTY, TASE: BOLT) ("BioLight" or the "Company"), a firm that invests in, manages and commercializes biomedical innovations in ophthalmology and cancer diagnostics, announced today that presentations highlighting its IOPtiMate™ system for the treatment of glaucoma will be delivered at the Ophthalmology Futures European Forum and the XXXIII Congress of the European Society of Cataract & Refractive Surgeons ("ESCRS"), both taking place in the coming days in Barcelona, Spain.
The IOPtiMate[TM] system is based on CO2 laser technology that enables the performance of a unique filtration surgery to treat glaucoma without penetrating the inner part of the eyeball, thus allowing for substantial reductions in post-operative complications and use of eye drops compared with alternatives.
Presentation Details
"Why CLASS Should be the Gold Standard in Glaucoma Surgery"
Mr. Ronen Castro, CEO, IOPtima Ltd.
Ophthalmology Futures European Forum
Fairmont Rey Juan Carlos 1 Hotel, Barcelona
September 3, 2015 at 2:01 p.m.
"Phacoemulsification of CLASS Short-term Results"
Professor E. Wylegala, Head of the Department of Ophthalmology, OSK Hospital Katowice
Congress of the ESCRS
Fira Gran Via, Barcelona
September 5, 2015 at 8:30 a.m.
"Five Years Follow-up of CLASS in Open-angle Glaucoma Patients"
Professor N. Geffen, Department of Ophthalmology, Meir Medical Center
Congress of the ESCRS
Fira Gran Via, Barcelona
September 7, 2015 at 8:00 a.m.
"As interest in the clinical benefits of IOPtiMate[TM] grows, it is important that we continue to drive awareness and acceptance of this unique surgical system amongst researchers, regulators and clinicians through presentations at important meetings like these," commented BioLight's Chief Executive Officer, Suzana Nahum Zilberberg.
